Verrica制药启动Ycanth®(VP-102)治疗寻常疣三期临床项目 首位患者完成给药

美股速递
Jan 07

Verrica Pharmaceuticals Inc. (VRCA) 宣布,其针对寻常疣治疗的三期临床试验项目已完成首位患者给药。该研究旨在评估候选药物Ycanth®(VP-102)的疗效与安全性。

作为一款创新疗法,Ycanth®若通过临床验证,有望为常见皮肤疾病患者提供新的治疗选择。此次三期项目的推进标志着该药物研发进入关键阶段。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10